Amid rising demand for GLP-1 drugs, healthcare-insurance company Cigna introduced two new programs to reduce costs and support patients. EnReachRX and EnGuide—the new initiatives—hope to enhance drug adherence and improve pharmacy services.
Notably, both programs are under Evernorth, Cigna’s health services division.
EnReachRx by Cigna
EnReachRx is a patient support program for pharmacies dispensing GLP-1 drugs like Ozempic and Wegovy. In particular, the program focuses on improving patient experience and safety.
First, it helps optimize medication dosage and detect fraud, waste, and abuse. Moreover, it monitors adherence and provides educational tools. Specifically, these tools support patients in managing complex treatment routines.
Additionally, EnReachRx offers flexibility in prescription durations—either 30 or 90 days, depending on coverage. It provides incentives to participating pharmacies in the form of a professional service fee. Consequently, this rewards them for offering extra clinical care.
Therefore, EnReachRx not only boosts compliance but also controls inappropriate drug use.
EnGuide: Specialty Pharmacy
Alongside EnReachRx, Cigna introduced EnGuide, a new home delivery pharmacy focused solely on GLP-1 medications.
Unlike general pharmacies, EnGuide clinicians have specific experience in GLP-1 treatment. Correspondingly, these experts guide patients and address concerns proactively. Furthermore, EnGuide connects patients to manufacturer copay assistance programs, easing financial burdens.
As a result, the service makes GLP-1 therapy more accessible and manageable for patients at home.
Backed by Cigna Growth
Overall, Cigna’s timing is strategic. Currently, GLP-1 drugs now make up nearly 3% of total healthcare costs for employers covering them for weight loss.
The company already manages this financial impact through EncircleRx, a separate program that provides cost guarantees for GLP-1s. Notably, EncircleRx now serves 9 million members.
In Q1 2025, Cigna posted a $1.3 billion profit. Due to strong GLP-1 demand, specialty pharmacy revenue has jumped 19% year-over-year. Clearly, the launch of EnReachRx and EnGuide supports both patient care and Cigna’s bottom line.
Industry Positioning and Edge
To clarify, Cigna’s strategy differs from competitors like CVS Caremark, which recently restricted coverage to select GLP-1 brands. Instead, Cigna supports a brand-agnostic approach.
Through Evernorth, the company is investing in comprehensive patient engagement and medication management. Consequently, this positions Cigna as a leader in navigating high-cost drug categories.
However, challenges remain, as regulatory scrutiny of GLP-1s is growing. Moreover, long-term data on sustained weight loss and health outcomes is still emerging.
Even so, Cigna is betting on a proactive model that emphasizes transparency and patient support.
Looking Ahead
By launching EnReachRx and EnGuide, Cigna takes a bold step to manage the complexities of GLP-1 medications. Overall, these programs may reduce waste, boost patient engagement, and lower costs.
Going forward, other payers may adopt similar strategies as pressure mounts to manage high-demand drugs. If successful, Cigna’s approach could become a blueprint for future medication support systems.
Ultimately, these efforts highlight the intersection of innovation, patient care, and financial stewardship in today’s healthcare landscape.
Cigna office building by Thomas Nugent, CC BY-SA 2.0, via Wikimedia Commons
